Polen Capital Exits Boston Scientific Position Amid Competitive Pressures

Polen Capital has announced the complete sale of its stake in medical technology firm Boston Scientific (BSX). The decision was detailed in the firm's first-quarter 2026 investor letter for its Polen Focus Growth Strategy, signaling a shift in the fund's conviction regarding the company's market position. The divestment was primarily driven by concerns regarding the competitive landscape facing Boston Scientific. By exiting the position, Polen Capital is reassessing its exposure to the healthcare technology sector in light of evolving industry dynamics. This strategic shift occurs against a backdrop of significant macroeconomic instability. According to the investor letter, the first quarter of 2026 was characterized by high volatility across US equities. The firm identified two primary catalysts for this turbulence: ongoing concerns regarding AI-driven disruption and escalating geopolitical conflicts involving the US, Israel, and Iran in the Middle East. While the exit reflects the specific strategic outlook of Polen Capital, it underscores the broader challenge growth-oriented funds face when balancing long-term competitive viability against immediate geopolitical and technological headwinds.